Cover Image
市場調查報告書

α-半乳糖苷酶A:開發平台分析

Alpha Galactosidase A (Alpha D-Galactosidase A or Alpha D Galactoside Galactohydrolase or Melibiase or Agalsidase or GLA or EC 3.2.1.22) - Pipeline Review, H2 2016

出版商 Global Markets Direct 商品編碼 359840
出版日期 內容資訊 英文 64 Pages
訂單完成後即時交付
價格
Back to Top
α-半乳糖苷酶A:開發平台分析 Alpha Galactosidase A (Alpha D-Galactosidase A or Alpha D Galactoside Galactohydrolase or Melibiase or Agalsidase or GLA or EC 3.2.1.22) - Pipeline Review, H2 2016
出版日期: 2016年09月30日 內容資訊: 英文 64 Pages
簡介

本報告提供以α-半乳糖苷酶A為標的的藥物之適應症,開發階段,作用機制,給藥途徑及各分子類型分析,提供您藥物的藥理作用相關記述,迄今的研究開發趨勢,最新的新聞和發表,藥物的主要開發企業概要,休止/中止的計劃等資訊。

簡介

  • 調查範圍

α-半乳糖苷酶A概要

治療藥的開發

α-半乳糖苷酶A:開發中的產品 - 各開發階段

α-半乳糖苷酶A:開發中的產品 - 各治療範圍

α-半乳糖苷酶A:開發中的產品 - 各適應症

α-半乳糖苷酶A:開發中產品概況

  • 後期階段的產品
  • 初期階段的產品

α-半乳糖苷酶A:企業開發中的產品

α-半乳糖苷酶A:治療藥的評估

  • 單劑療法/聯合治療產品別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

α-半乳糖苷酶A的治療藥開發企業

  • Amicus Therapeutics, Inc.
  • greenovation Biotech GmbH
  • iBio, Inc.
  • ISU ABXIS Co.,Ltd.
  • JCR Pharmaceuticals Co., Ltd.
  • Pharming Group N.V.
  • Protalix BioTherapeutics, Inc.
  • Shire Plc

藥物簡介

α-半乳糖苷酶A:暫停中的計劃

α-半乳糖苷酶A:開發中止的產品

α-半乳糖苷酶A:主要消息和新聞稿

附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC0558TDB

Summary

Global Markets Direct's, 'Alpha Galactosidase A (Alpha D-Galactosidase A or Alpha D Galactoside Galactohydrolase or Melibiase or Agalsidase or GLA or EC 3.2.1.22) - Pipeline Review, H2 2016', provides in depth analysis on Alpha Galactosidase A (Alpha D-Galactosidase A or Alpha D Galactoside Galactohydrolase or Melibiase or Agalsidase or GLA or EC 3.2.1.22) targeted pipeline therapeutics.

The report provides comprehensive information on the Alpha Galactosidase A (Alpha D-Galactosidase A or Alpha D Galactoside Galactohydrolase or Melibiase or Agalsidase or GLA or EC 3.2.1.22) , targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Alpha Galactosidase A (Alpha D-Galactosidase A or Alpha D Galactoside Galactohydrolase or Melibiase or Agalsidase or GLA or EC 3.2.1.22) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note:

Certain sections in the report may be removed or altered based on the availability and relevance of data.

Updated report will be delivered in 48 hours of order confirmation.

Scope

  • The report provides a snapshot of the global therapeutic landscape for Alpha Galactosidase A (Alpha D-Galactosidase A or Alpha D Galactoside Galactohydrolase or Melibiase or Agalsidase or GLA or EC 3.2.1.22)
  • The report reviews Alpha Galactosidase A (Alpha D-Galactosidase A or Alpha D Galactoside Galactohydrolase or Melibiase or Agalsidase or GLA or EC 3.2.1.22) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Alpha Galactosidase A (Alpha D-Galactosidase A or Alpha D Galactoside Galactohydrolase or Melibiase or Agalsidase or GLA or EC 3.2.1.22) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Alpha Galactosidase A (Alpha D-Galactosidase A or Alpha D Galactoside Galactohydrolase or Melibiase or Agalsidase or GLA or EC 3.2.1.22) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Alpha Galactosidase A (Alpha D-Galactosidase A or Alpha D Galactoside Galactohydrolase or Melibiase or Agalsidase or GLA or EC 3.2.1.22) targeted therapeutics

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Alpha Galactosidase A (Alpha D-Galactosidase A or Alpha D Galactoside Galactohydrolase or Melibiase or Agalsidase or GLA or EC 3.2.1.22)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Alpha Galactosidase A (Alpha D-Galactosidase A or Alpha D Galactoside Galactohydrolase or Melibiase or Agalsidase or GLA or EC 3.2.1.22) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Alpha Galactosidase A (Alpha D-Galactosidase A or Alpha D Galactoside Galactohydrolase or Melibiase or Agalsidase or GLA or EC 3.2.1.22) Overview
  • Therapeutics Development
    • Alpha Galactosidase A (Alpha D-Galactosidase A or Alpha D Galactoside Galactohydrolase or Melibiase or Agalsidase or GLA or EC 3.2.1.22) - Products under Development by Stage of Development
    • Alpha Galactosidase A (Alpha D-Galactosidase A or Alpha D Galactoside Galactohydrolase or Melibiase or Agalsidase or GLA or EC 3.2.1.22) - Products under Development by Therapy Area
    • Alpha Galactosidase A (Alpha D-Galactosidase A or Alpha D Galactoside Galactohydrolase or Melibiase or Agalsidase or GLA or EC 3.2.1.22) - Products under Development by Indication
  • Alpha Galactosidase A (Alpha D-Galactosidase A or Alpha D Galactoside Galactohydrolase or Melibiase or Agalsidase or GLA or EC 3.2.1.22) - Pipeline Products Glance
    • Late Stage Products
    • Early Stage Products
  • Alpha Galactosidase A (Alpha D-Galactosidase A or Alpha D Galactoside Galactohydrolase or Melibiase or Agalsidase or GLA or EC 3.2.1.22) - Products under Development by Companies
  • Alpha Galactosidase A (Alpha D-Galactosidase A or Alpha D Galactoside Galactohydrolase or Melibiase or Agalsidase or GLA or EC 3.2.1.22) - Therapeutics Assessment
    • Assessment by Monotherapy/Combination Products
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Alpha Galactosidase A (Alpha D-Galactosidase A or Alpha D Galactoside Galactohydrolase or Melibiase or Agalsidase or GLA or EC 3.2.1.22) - Companies Involved in Therapeutics Development
    • Amicus Therapeutics, Inc.
    • greenovation Biotech GmbH
    • JCR Pharmaceuticals Co., Ltd.
    • Pharming Group N.V.
    • Protalix BioTherapeutics, Inc.
    • Shire Plc
  • Alpha Galactosidase A (Alpha D-Galactosidase A or Alpha D Galactoside Galactohydrolase or Melibiase or Agalsidase or GLA or EC 3.2.1.22) - Drug Profiles
    • agalsidase alfa - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • agalsidase alfa - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • AVR-02 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Enzyme Replacement Therapy + migalastat hydrochloride Biobetter - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • migalastat hydrochloride - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • MOSS-AGAL - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • pegunigalsidase alfa - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Recombinant Alpha-Galactosidase A Replacement for Fabry's Disease - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Alpha Galactosidase A (Alpha D-Galactosidase A or Alpha D Galactoside Galactohydrolase or Melibiase or Agalsidase or GLA or EC 3.2.1.22) - Dormant Projects
  • Alpha Galactosidase A (Alpha D-Galactosidase A or Alpha D Galactoside Galactohydrolase or Melibiase or Agalsidase or GLA or EC 3.2.1.22) - Discontinued Products
  • Alpha Galactosidase A (Alpha D-Galactosidase A or Alpha D Galactoside Galactohydrolase or Melibiase or Agalsidase or GLA or EC 3.2.1.22) - Featured News & Press Releases
    • Sep 07, 2016: Protalix BioTherapeutics Announces Presentation of Results from the Phase I/II Clinical Trial of PRX-102 for the Treatment of Fabry Disease at the Society for the Study of Inborn Errors of Metabolism
    • Aug 31, 2016: Amicus Therapeutics to Highlight Fabry Disease Program at Society for the Study of Inborn Errors of Metabolism Annual Symposium
    • Aug 10, 2016: New England Journal of Medicine Publishes Pivotal Phase 3 FACETS Study of Migalastat for Patients with Fabry Disease
    • Aug 10, 2016: Protalix BioTherapeutics Announces Additional Positive Data from its Phase I/II Clinical Trial for PRX-102 for the Treatment of Fabry Disease
    • Aug 03, 2016: Amicus Therapeutics to Submit Japanese New Drug Application for Migalastat for Fabry Disease in 1H17
    • Aug 02, 2016: Almac Group's Integrated Development to Commercialisation Services Support Amicus Therapeutics' First Commercial Orphan Drug Product
    • Jun 06, 2016: Protalix BioTherapeutics Initiates PRX-102 Global Phase III Clinical Trial of Fabry Disease to Support United States and European Filings
    • May 31, 2016: Amicus Therapeutics Announces European Commission Approval for Galafold (Migalastat) in Patients with Fabry Disease in European Union
    • Apr 01, 2016: Amicus Therapeutics Receives Positive CHMP Opinion for Approval of Migalastat in Patients with Fabry Disease in European Union
    • Apr 01, 2016: First oral treatment for Fabry disease recommended for approval in the EU
    • Mar 22, 2016: Amicus Therapeutics Announces Expanded Access Program for Migalastat
    • Mar 03, 2016: Protalix BioTherapeutics Presents Positive Six and Twelve Month Interim Clinical Data on PRX-102 for the Treatment of Fabry Disease at the 12th Annual WORLDSymposium 2016
    • Mar 01, 2016: Amicus Therapeutics Highlights New Phase 3 Fabry Data at WORLDSymposium 2016
    • Feb 22, 2016: Protalix BioTherapeutics to Participate in the SunTrust Robinson Humphrey Orphan Drug Day and the 12th Annual WORLDSymposium 2016
    • Feb 10, 2016: Amicus Therapeutics Announces Presentations on Migalastat at 12th Annual WORLDSymposium 2016
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for, H2 2016
  • Number of Products under Development by Therapy Area, H2 2016
  • Number of Products under Development by Indication, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Early Stage Products, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Products under Development by Companies, H2 2016
  • Assessment by Monotherapy/Combination Products, H2 2016
  • Number of Products by Stage and Mechanism of Action, H2 2016
  • Number of Products by Stage and Route of Administration, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
  • Pipeline by Amicus Therapeutics, Inc., H2 2016
  • Pipeline by greenovation Biotech GmbH, H2 2016
  • Pipeline by JCR Pharmaceuticals Co., Ltd., H2 2016
  • Pipeline by Pharming Group N.V., H2 2016
  • Pipeline by Protalix BioTherapeutics, Inc., H2 2016
  • Pipeline by Shire Plc, H2 2016
  • Dormant Projects, H2 2016
  • Discontinued Products, H2 2016

List of Figures

  • Number of Products under Development for, H2 2016
  • Comparative Analysis by Early Stage Products, H2 2016
  • Assessment by Monotherapy/Combination Products, H2 2016
  • Number of Products by Stage and Mechanism of Action, H2 2016
  • Number of Products by Routes of Administration, H2 2016
  • Number of Products by Stage and Routes of Administration, H2 2016
  • Number of Products by Molecule Types, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
Back to Top